在2型糖尿病中,Miro1调解了骨肌肉对胰岛素的抵抗
medRxiv : the preprint server for health sciences
|October 1, 2025
概括
运动训练逆转了线粒体Rho GTPase 1 (Miro1) 在骨肌肉中的积累,改善了2型糖尿病 (T2D) 患者的胰岛素敏感性和葡萄糖平衡.
科学领域:
- 线粒体生物学 线粒体生物学
- 代谢性疾病是一种代谢性疾病.
- 运动生理学 运动生理学
背景情况:
- 不平衡的骨肌线粒体动力学与2型糖尿病 (T2D) 病原发生有关.
- 精确的机制,特别是线粒体Rho GTPase 1 (Miro1) 的作用,仍然不清楚.
- 在肥胖和T2D患者的骨肌肉中积聚Miro1.
研究的目的:
- 调查Miro1在骨肌肉胰岛素作用和T2D中的葡萄糖平衡中的作用.
- 确定运动训练是否可以逆转Miro1积累并改善T2D中的代谢功能.
- 使用小鼠模型确定Miro1和葡萄糖代谢之间的因果关系.
主要方法:
- 对24名T2D患者的前性研究,随机分配给12周的标准护理或运动训练.
- 评估骨肌肉的Miro1表达,线粒体功能和胰岛素敏感性.
- 生成肌肉特异性Miro1功能丧失的小鼠和细胞模型.
主要成果:
- 运动训练显著减少了T2D患者的骨肌肉Miro1积累.
- 运动增强了线粒体的氧化能力和胰岛素敏感性.
- 在小鼠中,肌肉特异性的Miro1缺失改善了胰岛素作用和氧化能力.
结论:
- 骨肌肉Miro1积累是T2D病理生理学的关键因素.
- 运动训练是一种有效的干预措施,可以减少Miro1并改善T2D中的代谢健康.
- 向Miro1可能为T2D提供治疗策略.
相关概念视频
Insulin: The Receptor and Signaling Pathways
2.8K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones
585
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
585
Diabetes Mellitus: Overview and Type I Subtype
4.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.9K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Dipeptidyl Peptidase 4 Inhibitors
594
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
594


